

Clinical Significance of Escherichia coli O157:H7 and Its Plasmid O157 – A review

Anurag¹, Gyanendra Krishna Pandey^{1*}, Harsh Kumar¹, Cheenmai Singh¹

¹Department of Pharmacy Practice, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be university), Mullana - 133207, Ambala, Haryana, India

Date of Submission: 01-05-2024

Date of Acceptance: 10-05-2024

ABSTRACT

Enterohemorrhagic Escherichia coli O157:H7 is a common foodborne pathogen that causes serious illness in humans across the world. Bovine food items and fresh produce contaminated with bovine faeces are the most prevalent origins of disease outbreaks in the United States, and healthy cattle are a reservoir for E. coli O157:H7. E. coli O157:H7 is also a good survivor in the environment. E. coli O157:H7 must be able to adapt to a wide range of environments in order to cause human illness, colonise the bovine gastrointestinal system, and live in the environment. Shiga toxins, products of the pathogenicity island dubbed the locus of enterocyte effacement, and products of the F-like plasmid pO157 have all been identified as important virulence factors of E. coli O157:H7. pO157 has an important role among these virulence variables. The role of pO157 is the least known of these virulence factors. This article gives a general overview of E. coli O157:H7, with a focus on pO157.

Keywords

E. coli O157:H7, pO157

I. ESCHERICHIA COLI O157:H7

Escherichia coli (E. coli) is a Gram-negative, rod-shaped, facultative anaerobic bacteria. Theodor Escherich was the first to characterise this bacterium in 1885. The majority of E. coli strains inhabit people and animals' gastrointestinal tracts as natural flora. However, certain strains of E. coli have developed into pathogenic E. coli as a result of virulence factors acquired via plasmids, transposons, bacteriophages, and/or pathogenicity islands. Serogroups, pathogenicity mechanisms, clinical symptoms, and virulence factors can all be used to classify pathogenic E. coli [33, 47]. Enterohemorrhagic E. coli (EHEC) is a kind of pathogenic E. coli that produces Shiga toxins (Stxs) that causes hemorrhagic colitis (HC) and the potentially fatal

sequelae hemolytic uremic syndrome (HUS) in humans. Several EHEC serotypes, such as O26:H11, O91:H21, O111:H8, O157:NM, and O157:H7, have been linked to human illnesses [44, 51]. This study focuses on E. coli O157:H7, the most often isolated serotype of EHEC from unwell people in the United States, Japan, and the United Kingdom.

History

In 1982, EHEC serotype O157:H7 was identified as a human pathogen connected to epidemics of bloody diarrhoea in Oregon and Michigan, United States of America [57, 71], as well as rare instances of HUS in 1983 [34]. Since then, several EHEC outbreaks have been documented in the United States, and E. coli O157:H7 has emerged as one of the most dangerous foodborne infections.

Prevalence and Economic Cost

E. coli O157:H7 infections are projected to cause 73,000 illnesses, 2,200 hospitalizations, and 60 fatalities in the United States each year by the Centers for Disease Control and Prevention (CDC) [43]. According to CDC outbreak monitoring statistics, E. coli O157:H7 infections are declining following a high in 1999. Large outbreaks and isolated instances, however, continue to occur. E. coli O157:H7 infections cost \$405 million per year in lost productivity, medical treatment, and untimely deaths [21]. Because of the high expense of sickness, more effort is needed to combat this infection.

Isolation and Identification

Somatic (O) antigen 157 and flagella (H) antigen 7 are both expressed by E. coli O157:H7. E. coli O157:H7 is distinguished by its inability to produce -glucuronidase, which can hydrolyze the synthetic compound 4-methyl-umbelliferyl-D-

glucuronide (MUG) [68] and its delayed D-sorbitol fermentation (>24 h). For the detection of *E. coli* O157:H7, Sorbitol MacConkey (SMAC) agar spiked with MUG was utilised. Cefixime, potassium tellurite, and vancomycin have been added to SMAC agar plates to boost the selectivity for *E. coli* O157:H7 and to suppress other Gram-negative flora. A commercially available latex agglutination assay can be used to confirm serotypes O157 and H7.

Genomic Organization

E. coli O157:H7 has a chromosomal size of 5.5 Mb. A 4.1 Mb backbone sequence found in all *E. coli* strains is included in this genome. The rest are only found in *E. coli* O157:H7 [53]. Furthermore, a genome comparison of *E. coli* O157:H7 and nonpathogenic *E. coli* K12 reveals that *E. coli* O157:H7 lacks 0.53 Mb of DNA, suggesting that genomic reduction had a role in *E. coli* O157:H7 evolution [17, 53]. Horizontally transmitted foreign DNAs such as prophage and prophage-like elements make up the bulk of *E. coli* O157:H7-specific DNA sequences (1.4 Mb). There are 463 phage-associated genes in *E. coli* O157:H7 compared to only 29 in *E. coli* K-12 [72]. Putonti et al. [55] calculated that at least 53 distinct species contributed to these unique sequences in *E. coli* O157:H7, and a change in G+C contents is one of the indicators that a genomic area has been acquired through horizontal transfer. Two sequenced *E. coli* O157:H7 strains had almost similar virulence-associated genes (99 percent). Both the acquisition and loss of DNA have clearly played a role in the development of *E. coli* O157:H7 pathogenesis.

Evolution

E. coli O157:H7 may have derived from the non-toxicogenic and less virulent strain *E. coli* O55:H7, according to several comparative and epidemiological research [72]. Acquisition of a stx2-containing bacteriophage, (ii) acquisition of pO157 and the rfb region, (iii) acquisition of the stx1-containing bacteriophage, and (iv) loss of the ability to ferment D-sorbitol and loss of beta-glucuronidase (GUD) activity were the four sequential events that led to the emergence of *E. coli* O15:H7.

Animal Reservoir

Cattle are the most common reservoir for *E. coli* O157:H7, and this reservoir host is usually asymptomatic when infected. This serotype has

been linked to a few occurrences of diarrheal illness in young calves. At any given period, the proportion of cattle shedding fluctuates. *E. coli* O157:H7 has also been detected in the faeces of sheep, goats, pigs, and turkeys.

Molecular Subtyping

To better understand the epidemiology of *E. coli* O157:H7 outbreaks, a range of molecular subtyping approaches have been developed. PFGE, restriction fragment length polymorphisms (RFLP), amplified fragment-length polymorphisms (AFLP), and phage typing are examples of these approaches [65, 73]. CDC standardised the PFGE technique, which has been used successfully to distinguish outbreak-associated, sporadic, or unrelated illnesses since 1993 [3].

Infection

In North America, Europe, and other parts of the world, *E. coli* O157:H7 infection is a serious public health risk. Despite the fact that the overall number of *E. coli* O157:H7 infections is fewer than other enteric pathogens like *Salmonella* or *Campylobacter* spp., the illnesses caused by *E. coli* O157:H7 have substantially higher hospitalisation and death rates [43]. Human infection induced by *E. coli* O157:H7 can have a wide range of symptoms, from asymptomatic to fatal. The majority of cases begin with non-bloody diarrhoea and resolve on their own without further complications. In 1–3 days, however, some individuals have bloody diarrhoea or HC. The condition can proceed to life-threatening complications such as HUS or thrombocytopenic purpura (TTP) in 5–10% of HC patients [1]. In the United States, *E. coli* O157:H7 is the most prevalent cause of HUS. Severe clinical signs such as HUS are more common in children and the elderly.

Several treatment options have been investigated, including antibiotics and immunisation. Antibiotics may be contraindicated in the case of *E. coli* O157:H7 infection since there is no particular therapy. As a result, therapy is mostly supportive in nature, with the goal of limiting the duration of symptoms and preventing systemic consequences. Given this situation, extremely effective *E. coli* O157:H7 infection prevention and control strategies are critical.

Transmission

Consumption of contaminated food and water is the most common mode of transmission

for *E. coli* O157:H7 infections in the United States [56]. It can also be passed directly from person to person and from animal to human, especially in kid day-care centres. People who visited petting zoos, dairy farms, or camp areas where cattle had previously grazed have been infected [28, 31]. A polluted facility with an animal show has recently been identified as having the potential for airborne transmission [70]. Foodborne (52 percent), unknown (21 percent), person-to-person (14 percent), waterborne (9 percent), and animal contact (3 percent) were the established transmission pathways in the 350 outbreaks reported to the CDC between 1982 and 2002 [56]. Figure 1 depicts the *E. coli* O157:H7 transmission model, which has been revised from Gansheroff and O'Brien's model [23]. The relatively low infectious dosage (50 CFU) of *E. coli* O157:H7 explains the multiple transmission pathways. *E. coli* is found in cattle naturally. *E. coli* O157:H7 is a strain of *E. coli* that is resistant to antibiotic. *E. coli* is carried by and shed by between 1% and 50% of healthy cattle. At any one moment, they may have *E. coli* O157:H7 in their faeces [13, 18, 27]. *E. coli* is most commonly spread through contaminated ground beef. Outbreaks of *E. coli* O157:H7 During slaughter, germs can enter beef products, and the grinding process can transmit infections from the meat's surface to its inside. As a result, germs can persist if ground beef is not thoroughly cooked. In addition to ground beef, a number of other contaminated food vehicles have been connected to *E. coli* O157:H7 outbreaks, including unpasteurized milk, drinking water, salami, beef jerky, and fresh vegetables like lettuce, radish sprouts, fresh spinach, and apple cider. The greatest incidence was linked to radish sprout contamination in Osaka, Japan, in 1996, when 7,966 people were diagnosed with illnesses [45]. These food products appear to have been contaminated with bovine faeces, according to epidemiological investigations. As a result, one of the most significant management techniques for *E. coli* O157:H7 in cattle is to avoid it.

Acid Resistance of *E. coli* O157:H7

The capacity of bacteria to protect themselves against extremely low pH (pH 3.0) is known as acid resistance (AR). One of the initial host defences against foodborne enteric infections is a low pH in the stomach (pH 1.5 to 3.0) [54]. Bacteria that can live in the acidic environment of the stomach have a greater chance of colonising the intestines and causing illness. Acid resistance has

been linked to a reduction in enteric pathogen infectious doses [60]. One of the most well-known properties of *E. coli* O157:H7 is its low infectious dosage, which makes it extremely contagious. The AR of *E. coli* O157:H7 strains has been documented in several investigations [5, 12]. Three effective AR systems were discovered as a result of these researches. RpoS, an alternate sigma factor, and glucose repression are required for the first AR system. In experimentally infected mice and calves, the rpoS mutant of *E. coli* O157:H7 shed in reduced quantities. The addition of arginine to the second AR system is required after acidic exposure. This second AR system revealed the arginine decarboxylase (*adiA*) and the *adiA* regulator (*cysB*). For protection in low pH conditions, the third AR system requires glutamate. Two glutamate decarboxylase isozymes (*gadA* and *gadB*), as well as a suspected glutamate, -amino butyric acid antiporter, are essential components of this AR system (*gadC*). At pH 2.5, just one of the two glutamate decarboxylase isozymes is required for protection, but at pH 2.0, both are required. Previous research has shown that glutamate-dependent AR provides the most efficient protection in complex media at pH 2.0. *E. coli* O157:H7 has three AR systems that overlap, but each AR system's control and needs for AR activity are different.

Several proteins involved in *E. coli* O157:H7 AR have been found in addition to these three AR systems. Chaperone HdeA, RNA polymerase-associated protein SspA, and DNA-binding protein Dps are among these proteins. Furthermore, it was discovered that changes in the cell wall membrane or colonic acid production are linked to AR success.

Colonization of Cattle

E. coli O157:H7 naturally colonises cattle's gastrointestinal tracts, and the rectoanal junction (RAJ) mucosa, a lymphoid follicle-dense mucosa near the distal rectum, is recognised to be a primary site of colonisation in cattle [39, 48].

There have previously been three unique patterns of *E. coli* O157:H7 carriage in cattle [14, 39, 58]. For starters, animals can remain culture positive for a few days and are termed passive shedders, meaning they are unlikely to colonise the RAJ mucosa. Second, cattle can be colonised and shed germs for an average of one month, but seldom more than two months.

Finally, a few uncommon animals get colonised for an extended period of time and shed

germs for 3 to 12 months or longer. This unusual condition, in which a few animals acquire long-term *E. coli* O157:H7 colonisation (>2 months), is most likely owing to bacterial association at the RAJ mucosa; however, it might also be due to the bacteria colonising a site(s) other than the RAJ mucosa.

Individual cattle's age, food, and immunity may all have an impact on bacterial colonisation. Calves shed *E. coli* O157:H7 for longer than adult cattle when given the same quantity of *E. coli* O157:H7 inoculums, according to Cray and Moon [14]. Reducing *E. coli* O157:H7 carriage in cattle, which is a significant source of *E. coli* O157:H7 infection, would help to reduce the risk of human infection. Understanding *E. coli* O157:H7 colonisation factors will be crucial for developing successful methods for minimising or preventing *E. coli* O157:H7 carriage in cattle.

Environmental Survival

E. coli O157:H7 may survive and persist in a variety of settings, including soil, water, food, and animal reservoirs (Fig. 2). *E. coli* O157:H7 has been shown to persist for a year in manure-treated soil and for 21 months in raw, uncomposted manure [30]. If the temperature is kept above 50°C for 6 days, composting manure is efficient in killing *E. coli* O157:H7. *E. coli* O157:H7 may persist in water for a long period, particularly at low temperatures. Water trough sediments polluted with bovine excrement can serve as a long-term (>8 months) reservoir of *E. coli* O157:H7, and the bacteria that survive in contaminated troughs can cause illness [38]. *E. coli* O157:H7 lives and replicates in *Acanthamoeba polyphaga*, according to Barker et al. [2]. *A. polyphaga* is a widespread environmental protozoan that may be found in soil, water, and faeces. As a result, it might be an effective *E. coli* O157:H7 transmission vehicle in these conditions. *E. coli* O157:H7 requires the capacity to adapt to fluctuations or dramatic changes in temperature, pH, and osmolarity that occur in nature in order to thrive in a variety of situations. For example, the generation of exopolysaccharide (EPS) by *E. coli* O157:H7 is linked to heat and acid tolerance, and heat stress causes changes in lipid content in membranes [77].

These environmental adaptations of *E. coli* O157:H7 are critical for the microorganism's survival and spread on farms, as well as the increased transmission from cattle to cattle. Furthermore, the pathogen's capacity to live outside of the host reservoir raises the possibility of

contamination of crops and products through bovine dung pollution, irrigation with contaminated water, or direct contact with sick animals [42].

Major Virulence Factors

Numerous research have focused on defining the virulence factors and processes of *E. coli* O157:H7 pathogenesis (Fig. 3). Although the generation of Stxs is thought to be important, it is not completely responsible for illness. Furthermore, *E. coli* O157:H7, which has been linked to severe human disease, must colonise the intestinal mucosa, and the presence of pO157 is linked to the capacity to induce disease. Each of these features is discussed in detail below.

Shiga Toxins (Stxs)

Stx is a bacteriophage-encoded cytotoxin with a high potency. Stx is a single transcriptional unit that has been extended to induce harm to a range of cell types [29]. Stxs are separated into two groups: Stx1 and Stx2, although they do not produce cross-reactive antibodies since their amino acid sequences are 56 percent identical. The only difference between Stx1 and Stx from *Shigella dysenteriae* I is a single amino acid. Stx1 exclusively, Stx2 solely, or both toxins can be expressed by virulent *E. coli* O157:H7 strains. Stx2 strains are known to be more hazardous than Stx1 strains and are more frequently linked with HC or HUS in human infections [6, 50].

One enzymatically active A subunit (A1) and five identical receptor-binding B subunits make up Stx's structure (B5). The B5 subunit interacts to the globotriaosylceramide (Gb3) or globotetraosylceramide (Gb4) host receptors [47]. The A subunit is internalised to the cytoplasm after Stx (A1B5) binds to the host cell. A1 suppresses protein synthesis by removing a single adenine residue from the 60S ribosomal subunit's 28S rRNA [59]. The precise processes of Stx translocation to different tissues are unknown.

The Locus of Enterocyte Effacement

Attaching and effacing (A/E) lesions are a kind of histopathological lesion caused by *E. coli* O157:H7 colonisation of the intestinal mucosa. Microvilli effacement and bacterial adhesion to the epithelial cell membrane are two characteristics of the A/E lesion. Attached bacteria increase the amount of actin polymerization in the host cell, resulting in a higher attachment pedestal [11]. The genes that cause A/E lesions are found in a 13-region called the locus of enterocyte effacement,

according to genetic research (LEE). The LEE of *E. coli* O157:H7 is also preserved in EPEC, and the presence of the LEE is well recognised to be related with illness [24]. When compared to EPEC strains, the LEE of *E. coli* O157:H7 is 43 kb in size and contains an extra 7.5 kb prophage sequence. The function of this extra sequence is unclear. The LEE is made up of at least 41 genes organised into three major regions: (i) a type III secretion system (TTSS) that exports effector molecules; (ii) an adhesion called intimin and its translocated receptor, Tir, which is translocated into the host cell membrane by the TTSS; and (iii) several secreted proteins (Esp) as a part of the TTSS, which are important in the modification of host cell signal transduction during the formation of A/E lesions [15, 52]. Non-LEE encoded effectors have recently been discovered, and elucidating their functions will help us better comprehend the pathogenic events in *E. coli* O157:H7 infections [16].

Plasmid O157 (pO157)

A plasmid is a piece of extrachromosomal DNA that can replicate without the help of chromosomal DNA. Plasmids are mobile components that provide host advantages such as antibiotic and heavy metal resistance, the generation of poisons and other virulence factors, hydrocarbon biotransformations, and symbiotic nitrogen fixation [22]. Many enteropathogenic bacteria, such as *Shigella*, *Yersinia*, *Salmonella*, and *E. coli*, require plasmid-encoded genes for complete pathogenesis.

pO157

pO157 is a highly conserved plasmid found in *E. coli* O157:H7. The plasmid pO157 is a nonconjugative F-like plasmid with a range of 92 to 104 kb in size. The full sequencing of pO157 has been reported in two separate epidemic isolates [10, 41]. The plasmid pO157 has a dynamic structure and contains a variety of mobile genetic components such as transposons, prophages, insertion sequences (IS), and fragments from other plasmids. The co-responses to functional zones of pO157 can be delimited by the heterogeneous composition of pO157. IS or IS remnants are typically coupled with virulence-related regions, which are comparable to the components of *Shigella* spp big 's virulence plasmid [10, 41]. These findings suggest that the genuine pO157 is generated by the integration of fragments from evolutionarily distinct species origins into an F-like

plasmid, and hence the virulence factors or potential virulence factors on the various segments of pO157 may come from various origins. The whole pO157 sequence has 100 open reading frames (ORFs) [10]. 43 ORFs had enough resemblance to known proteins to indicate functions, whereas 22 ORFs had no credible match to any known proteins. Thirty-five proteins are thought to be involved in the pathogenesis of *E. coli* O157:H7 infections, but only 19 genes have been identified, including a hemolysin (ehxA) [63], a catalase-peroxidase (katP) [9], a type II secretion system apparatus (etp) [62], a serine protease (espP) [8], a putative adhesin (to The biological importance of pO157 in pathogenesis, however, remains unknown.

Hemolysin (ehx)

Hemolysin was the first pO157 virulence component to be discovered [4, 61]. Because it possesses a different G+C percent and codon use than the surrounding genetic components, the hemolysin operon (ehxCABD) might be of foreign origin. The genes essential for hemolysin production and transport are encoded by a 3.4-kb fragment, which has been utilised as a diagnostic probe for *E. coli* O157:H7 and EHEC isolates. Several investigations have found that hemolysin is largely conserved among EHEC serotypes such as O157:H7, O111:H8, and O8:H19, however it is unknown if they have the same biological functions [7].

Catalase-Peroxidase (katP)

From pO157, a gene for catalase-peroxidase activity (katP) was discovered [9]. The bacterial bifunctional catalase-peroxidase gene is extremely comparable to this gene, which is 2.2 kb in size. KatP enzyme activity was detected in both the cytoplasm and periplasm fractions of *E. coli* O157:H7. This enzyme is thought to be transported across the cytoplasmic membrane, based on the N-terminal signal sequence. All *E. coli* O157:H7 strains have the katP gene, however EPEC, ETEC, EIEC, and EAaggEC strains do not. This enzyme may aid *E. coli* O157:H7 colonisation of human intestines by lowering oxidative stress and using the by-product oxygen in low or no oxygen environments.

Type II Secretion System (T2SS) (etp)

The ORFs etpC to etpO encoded by pO157 are very similar to Gram-negative bacteria's T2SS [62]. These genes are near the hemolysin

gene. The *etp* and *ehx* genes were discovered to have an IS911-like insertion element positioned far away. *etp* genes were detected in all *E. coli* O157:H7 strains, some non-O157 EHEC strains, but not in EPEC, ETEC, EIEC, or EAggEC strains, similar to the *katP* gene. Although this T2SS is comparable to *Klebsiella oxytoca*'s pullulanase secretion route (*puO*), its function is unknown.

Serine Protease (*espP*)

EspP is a type V secreted serine protease encoded by *pO157* that has been shown to cleave pepsin A and human coagulation factor V [8]. *PssA* in EHEC O26:H-, *EspC* in EPEC, and *IgA1* protease in *Neisseria* species are examples of secreted or surface-bound proteins that are comparable to this extracellular enzyme [69]. *EspP* impacts calves' intestinal colonisation and adhesion to bovine primary intestinal epithelial cells, according to Dziva et al. [19]. Furthermore, *EspP*-mediated degradation of human coagulation factor V might play a role in the mucosal bleeding seen in HC patients.

Metalloprotease (*stcE*)

StcE, a metalloprotease encoded on *pO157*, cleaves the C1 esterase inhibitor particularly [37]. Multiple proteolytic cascades associated to inflammatory pathways, including as classical complement, intrinsic coagulation, and contact activation, are regulated by the C1 esterase inhibitor. T2SS encoded on *pO157* secretes *StcE*, which is controlled by the LEE-encoded regulator (*ler*) [20, 37]. *StcE* can contribute to *E. coli* O157:H7 adhesion to Hep2 cells in vitro, according to Grys et al. [25]. The *stcE* gene was detected in all *E. coli* O157:H7 strains, some EPEC serotype O55:H7 strains, and none of the other diarrheagenic *E. coli* strains.

Putative Adhesion (*toxB*)

The *toxB* gene is encoded by a 9.5-kilobyte sequence, and its projected product shares 20% of its amino acid sequence with *Clostridium difficile* toxin B [41]. *ToxB* promotes *E. coli* O157:H7 adhesion to Caco-2 cells by increasing the production of TTSS, according to recent research [67]. Furthermore, a sequence analysis indicated that *ToxB* has 28% amino acid identity and 47% similarity to the anticipated product of *efa-1/lifA*, a virulence gene commonly located on the chromosome of EPEC and non-O157 EHEC isolates [46]. *ToxB* might be implicated in suppressing host lymphocytes because the *efa-1/*

lifA gene has been shown to prevent the activation of human and murine gastrointestinal lymphocytes [36]. In calves and lambs, however, a mutation in the *toxB* and *efa-1* genes had no effect on intestinal colonisation [66].

Eae Gene-Positive Conserved Fragments (*ecf*)

We recently discovered that *pO157* encodes the *ecf* operon (*ecf1-4*), which is temperature controlled by inherently curved DNA [76]. Both *ecf1* and *ecf2* are unique to *pO157* and encode a putative polysaccharide deacetylase and an LPS-1, 7-N-acetylglucosamine transferase, respectively [32]. *ecf3* resembles the putative outer membrane protein in *E. coli* K1, which has been linked to bacterial invasion [49]. The second copy of a lipid A myristoyl transferase is encoded by *ecf4*, also known as *msbB2* [35, 76]. The lipid A structure and membrane fatty acid composition of the double mutant bearing deletions in the *ecf4* and its chromosomal copy *lpxM* of *E. coli* O157:H7 were changed, and it demonstrated lower persistence in bovine gastrointestinal tracts [76]. However, when compared to wild-type *E. coli* O157:H7, a single *ecf4* mutation showed no significant change.

Pathogenesis of *pO157*

Following the first revelation that *pO157* was essential for the production of fimbriae and epithelial cell adhesion, other research [74] reported inconsistent results on the function of *pO157* in epithelial cell adhesion. Animal models such as the mouse, rabbit, and gnotobiotic piglet were used in in vivo investigations of *pO157*, with mixed results. In vivo investigations, on the other hand, have limitations due to the lack of an appropriate animal model that can replicate all elements of the illness. As a result, the exact involvement of *pO157* in the pathogenesis of *E. coli* O157:H7 remains unknown. We recently discovered that the *pO157* gene influences the effectiveness of *E. coli* O157:H7 colonisation and survival in acidic circumstances in healthy cattle [40, 64]. In comparison to wild type, an isogenic *pO157 E. coli* O157:H7 mutant is more resistant to acidic synthetic bovine gastric fluid and bile [40]. Higher glutamate decarboxylase (GAD) expression is responsible for the *pO157* mutant's increased acid resistance. The method by which *pO157* regulates *gad* is unknown, however it is most likely owing to *pO157* control of chromosomal genes. The *pO157* mutant survives transit through the gastrointestinal tracts of bovines better than wild

type, but it does not colonise the bovine RAJ mucosa as well as wild type [40, 64].

pO157-Like Plasmids in EHEC

Most non-O157 EHEC isolates, but not all human isolates, have large plasmids mimicking pO157, with sizes ranging from 70 to 200 kb [26]. The hemolysin operon (ehx) is generally carried by these plasmids, although the etpC-O, katP, and espP genes are detected in less than half of the isolates [11]. Some of these EHEC-hemolysin

plasmids have been linked to adhesion, whereas others have not. The presence of this EHEC-hemolysin plasmid is linked to the development of HUS rather than diarrhoea, according to epidemiological research. A variety of additional plasmids ranging in size from 2 to 87 kb have been found in *E. coli* O157:H7 isolates in addition to pO157 or EHEC-hemolysin plasmids. However, there has been no link discovered between the presence of any of these plasmids and clinical illness.

In vitro

| Year | Target | Pathogenesis | Effect |
|------|--------------------|--|--------|
| 1987 | Whole plasmid | Expression of fimbriae Adherence to epithelial cells | Yes |
| 1990 | Whole plasmid | Adherence to epithelial cells | Yes |
| 1993 | Whole plasmid | Production of pilli Adherence to epithelial cells | No |
| 2001 | toxB gene on pO157 | Adherence to epithelial cells | Yes |
| 2005 | stcE gene on pO157 | Adherence to epithelial cells | Yes |
| 2007 | espP gene on pO157 | Adherence to bovine primary intestinal epithelial cells | Yes |

In vivo

| Year | Target | Pathogenesis | Effect |
|------|--------------------|---|--------|
| 1987 | Whole plasmid | Attaching and effacing lesion in gnotobiotic piglets | No |
| 1990 | Whole plasmid | Colonization of mouse | No |
| 1993 | Whole plasmid | Clinical symptoms in rabbit | No |
| 2006 | Whole plasmid | Colonization of cattle | Yes |
| 2007 | Whole plasmid | Colonization of cattle | Yes |
| 2007 | espP gene on pO157 | Colonization of calves | Yes |

II. CONCLUSION

This article focuses on the *E. coli* O157:H7 serotype and its 92-kb plasmid. *E. coli* O157:H7 is a bacteria that causes serious human illness all over the world. Shiga toxins, products of the pathogenicity island known as the locus of enterocyte effacement, and products of the F-like plasmid pO157 are three key virulence factors. From its quiet reservoir in healthy cattle to the agricultural environment, this virus thrives in a variety of settings. Bacterial adhesion to eukaryotic cells, colonisation of cattle, and acid resistance are all influenced by genes expressed on the pO157.

Further research on the aetiology and persistence of *E. coli* O157:H7 in the environment will lead to more effective treatments to avoid human illness.

REFERENCES

- [1]. Banatvala N, Griffin PM, Greene KD, Barrett TJ, Bibb WF, Green JH, Wells JG. The United States National Prospective Hemolytic Uremic Syndrome Study: Microbiologic, serologic, clinical, and epidemiologic findings. *J Infect Dis.* 2001;183:1063–1070.

- [2]. Barker J, Humphrey TJ, Brown MW. Survival of *Escherichia coli* O157 in a soil protozoan: Implications for disease. *FEMS Microbiol Lett.* 1999;173:291–295.
- [3]. Barrett TJ, Lior H, Green JH, Khakhria R, Wells JG, Bell BP, Greene KD, Lewis J, Griffin PM. Laboratory investigation of a multistate food-borne outbreak of *Escherichia coli* O157:H7 by using pulsed-field gel electrophoresis and phage typing. *J Clin Microbiol.* 1994;32:3013–3017.
- [4]. Bauer ME, Welch RA. Characterization of an RTX toxin from enterohemorrhagic *Escherichia coli* O157:H7. *Infect Immun.* 1996;64:167–175.
- [5]. Benjamin MM, Datta AR. Acid tolerance of enterohemorrhagic *Escherichia coli*. *Appl Environ Microbiol.* 1995;61:1669–1672.
- [6]. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. Associations between virulence factors of Shiga toxin-producing *Escherichia coli* and disease in humans. *J Clin Microbiol.* 1999;37:497–503.
- [7]. Brashears MM, Galyean ML, Loneragan GH, Mann JE, Killinger-Mann K. Prevalence of *Escherichia coli* O157:H7 and performance by beef feedlot cattle given *Lactobacillus* direct-fed microbials. *J Food Prot.* 2003;66:748–754.
- [8]. Brunder W, Schmidt H, Karch H. EspP, a novel extracellular serine protease of enterohaemorrhagic *Escherichia coli* O157:H7 cleaves human coagulation factor V. *Mol Microbiol.* 1997;24:767–778.
- [9]. Brunder W, Schmidt H, Karch H. KatP, a novel catalase-peroxidase encoded by the large plasmid of enterohaemorrhagic *Escherichia coli* O157:H7. *Microbiology.* 1996;142:3305–3315.
- [10]. Burland V, Shao Y, Perna NT, Plunkett G, Sofia HJ, Blattner FR. The complete DNA sequence and analysis of the large virulence plasmid of *Escherichia coli* O157:H7. *Nucl Acids Res.* 1998;26:4196–4204.
- [11]. Caprioli A, Morabito S, Brugère H, Oswald E. Enterohaemorrhagic *Escherichia coli*: Emerging issues on virulence and modes of transmission. *Vet Res.* 2005;36:289–311.
- [12]. Castanie-Cornet MP, Penfound TA, Smith D, Elliott JF, Foster JW. Control of acid resistance in *Escherichia coli*. *J Bacteriol.* 1999;181:3525–3535.
- [13]. Cho S, Bender JB, Diez-Gonzalez F, Fossler CP, Hedberg CW, Kaneene JB, Ruegg PL, Warnick LD, Wells SJ. Prevalence and characterization of *Escherichia coli* O157 isolates from Minnesota dairy farms and county fairs. *J Food Prot.* 2006;69:252–259.
- [14]. Cray WC, Jr, Moon HW. Experimental infection of calves and adult cattle with *Escherichia coli* O157:H7. *Appl Environ Microbiol.* 1995;61:1586–1590.
- [15]. Delahay RM, Frankel G, Knutton S. Intimate interactions of enteropathogenic *Escherichia coli* at the host cell surface. *Curr Opin Infect Dis.* 2001;14:559–565.
- [16]. Deng W, Puente JL, Gruenheid S, Li Y, Vallance BA, Vázquez A, et al. Dissecting virulence: Systematic and functional analyses of a pathogenicity island. *Proc Natl Acad Sci USA.* 2004;101:3597–3602.
- [17]. Dobrindt U, Agerer F, Michaelis K, Janka A, Buchrieser C, Samuelson M, et al. Analysis of genome plasticity in pathogenic and commensal *Escherichia coli* isolates by use of DNA arrays. *J Bacteriol.* 2003;185:1831–1840.
- [18]. Dunn JR, Keen JE, Thompson RA. Prevalence of Shiga-toxigenic *Escherichia coli* O157:H7 in adult dairy cattle. *J Am Vet Med Assoc.* 2004;224:1151–1158.
- [19]. Dziva F, Mahajan A, Cameron P, Currie C, McKendrick IJ, Wallis TS, Smith DGE, Stevens MP. EspP, a type V-secreted serine protease of enterohaemorrhagic *Escherichia coli* O157:H7, influences intestinal colonization of calves and adherence to bovine primary intestinal epithelial cells. *FEMS Microbiol Lett.* 2007;271:258–264.
- [20]. Elliott SJ, Sperandio V, Giron JA, Shin S, Mellies JL, Wainwright L, Hutcheson SW,

- McDaniel TK, Kaper JB. The locus of enterocyte effacement (LEE)-encoded regulator controls expression of both LEE- and non-LEE-encoded virulence factors in enteropathogenic and enterohemorrhagic *Escherichia coli*. *Infect Immun*. 2000;68:6115–6126.
- [21]. Frenzen PD, Drake A, Angulo FJ. Economic cost of illness due to *Escherichia coli* O157 infections in the United States. *J Food Prot*. 2005;68:2623–2630.
- [22]. Frost LS, Leplae R, Summers AO, Toussaint A. Mobile genetic elements: The agents of open source evolution. *Nat Rev Microbiol*. 2005;3:722–732.
- [23]. Gansheroff LJ, O'Brien AD. *Escherichia coli* O157:H7 in beef cattle presented for slaughter in the US: Higher prevalence rates than previously estimated. *Proc Natl Acad Sci USA*. 2000;97:2959–2961.
- [24]. Griffin PM, Tauxe RV. The epidemiology of infections caused by *Escherichia coli* O157:H7, other enterohemorrhagic *E. coli*, and the associated hemolytic uremic syndrome. *Epidemiol Rev*. 1991;13:60–98.
- [25]. Grys TE, Siegel MB, Lathem WW, Welch RA. The StcE protease contributes to intimate adherence of enterohemorrhagic *Escherichia coli* O157:H7 to host cells. *Infect Immun*. 2005;73:1295–1303.
- [26]. Hales BA, Hart CA, Batt RM, Saunders JR. The large plasmids found in enterohemorrhagic and enteropathogenic *Escherichia coli* constitute a related series of transfer-defective Inc F-IIA replicons. *Plasmid*. 1992;28:183–193.
- [27]. Hancock DD, Besser TE, Rice DH, Herriott DE, Tarr PI. A longitudinal study of *Escherichia coli* O157 in fourteen cattle herds. *Epidemiol Infect*. 1997;118:193–195.
- [28]. Heuvelink AE, van Heerwaarden C, Zwartkruis-Nahuis JT, van Oosterom R, Edink K, van Duynhoven YT, de Boer E. *Escherichia coli* O157 infection associated with a petting zoo. *Epidemiol Infect*. 2002;129:295–302.
- [29]. Jacewicz MS, Acheson DW, Binion DG, West GA, Lincicome LL, Fiocchi C, Keusch GT. Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis. *Infect Immun*. 1999;67:1439–1444.
- [30]. Manish Kumar Maity, Mamta Naagar, "Autoimmune Neurogenic Dysphagia", *International Journal of Science and Research (IJSR)*, Volume 11 Issue 7, July 2022, pp. 447-463, https://www.ijsr.net/getabstract.php?paper_id=SR22630151732.
- [31]. Manish Kumar Maity, Mamta Naagar, "A Review on Headache: Epidemiology, Pathophysiology, Classifications, Diagnosis, Clinical Management and Treatment Modalities", *International Journal of Science and Research (IJSR)*, Volume 11 Issue 7, July 2022, pp. 506-515, https://www.ijsr.net/getabstract.php?paper_id=SR22703111804.
- [32]. Md Shamshir Alam , Manish Kumar Maity , Abdul Salam Nazmi , Md Sarfaraz Alam , Md Salahuddin Ansari. Oral Health Issues And Preventive Measures In Geriatric Populations. *Journal of Pharmaceutical Negative Results [Internet]*. 2022 Dec. 31 [cited 2023 Jun. 24];:2647-55. Available from: <https://www.pnrjournal.com/index.php/home/article/view/9175>
- [33]. Nikita Sharma , Md Shamshir Alam , Anubha Sharma , Sanyam Garg , Manish Kumar Maity. Colorectal Cancer In Young Adults: Epidemiology, Risk Factors, Development, Symptoms, Traditional Herbal Therapy And Prevention. *Journal of Pharmaceutical Negative Results [Internet]*. 2022 Dec. 31 [cited 2023 Jun. 24];:1370-82. Available from: <https://pnrjournal.com/index.php/home/article/view/6991>
- [34]. Ehteshamul Haque , Faiz Ahmed , Priyanka Chaurasiya , Neha Yadav , Nikita Dhiman , Manish Kumar Maity. A REVIEW ON ANTIDEPRESSANT EFFECT OF HERBAL DRUGS. *Journal of Pharmaceutical Negative Results [Internet]*. 2023 Feb. 17 [cited 2023 Jun. 24];:2716-23. Available from: <https://www.pnrjournal.com/index.php/home/article/view/8841>

- [35]. OmveerSingh, Shailesh Sharma, Mamta Naagar, Manish Kumar Maity, Eletriptan As Treatment Option For Acute Migraine, International Journal Of Innovations & Research Analysis (Ijira),02, 03(II), September, 2022, Pp 15-24.
- [36]. Priyanka Tanwar, Mamta Naagar, and Manish Kumar Maity, "Relationship between Type 2 Diabetes Mellitus and Osteoarthritis,"International Research Journal of Pharmacy and Medical Sciences (IRJPMS), Volume 6, Issue 2, pp. 59-70, 2023 (PDF) Relationship between Type 2 Diabetes Mellitus and Osteoarthritis. Available from: https://www.researchgate.net/publication/369022995_Relationship_between_Type_2_Diabetes_Mellitus_and_Osteoarthritis [accessed Jun 23 2023].
- [37]. Omveer Singh, Shailesh Sharma, Mamta Naagar, Manish Kumar Maity, Oral And Parenteral To Minimize The Nasal Delivery By Thermoreversible Mucoadhesive –A Review, International Journal Of Creative Research Thoughts (Ijcr), 09/2022,10(9) Pp.-356-371.
- [38]. Md Shamshir Alam, Garima Malik, Priyanka Tanwar, Mamta Naagar, Tarun Singh, Omveer Singh, Manish Kumar Maity, A Review on Small-Cell Lung Cancer: Epidemiology, Pathophysiology, RiskFactors, Diagnosis, Clinical Management and Treatment Modalities, International Journal of Current Science Research and Review (ijcsrr), 06(01): 129-151.
- [39]. Priyanka Tanwar, Mamta Naagar, and Manish Kumar Maity, "Relationship between Diabetes Mellitus and Bone Health – A Review,"International Research Journal of Pharmacy and Medical Sciences (IRJPMS), Volume 6, Issue 2, pp. 46-58, 2023. (PDF) Relationship between Diabetes Mellitus and Bone Health - A Review. Available from: https://www.researchgate.net/publication/369022910_Relationship_between_Diabetes_Mellitus_and_Bone_Health_-_A_Review [accessed Jun 23 2023].
- [40]. Manish Kumar Maity. A review on Helicobacter pylori Infection. ijmsdr [Internet]. 2022Sep.17 [cited 2023Jun.23];6(9). Available from: <https://www.ijmsdr.com/index.php/ijmsdr/article/view/950>
- [41]. Md Shamshir Alam , Manish Kumar Maity , Abdul Salam Nazmi , Md Sarfaraz Alam , Md Salahuddin Ansari (2022) "Oral Health Issues And Preventive Measures In Geriatric Populations",Journal of Pharmaceutical Negative Results, pp. 2647–2655. doi: 10.47750/pnr.2022.13.S10.316.
- [42]. Maule A. Survival of verocytotoxigenic Escherichia coli O157 in soil, water and on surfaces. Symp Ser Soc Appl Microbiol. 2000;29:71S–78S.
- [43]. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, Griffin PM, Tauxe RV. Food-related illness and death in the United States. Emerg Infect Dis. 1999;5:607–625.
- [44]. Melton-Celsa AR, Darnell SC, O'Brien AD. Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice. Infect Immun. 1996;64:1569–1576.
- [45]. Michino H, Araki K, Minami S, Takaya S, Sakai N, Miyazaki M, Ono A, Yanagawa H. Massive outbreak of Escherichia coli O157:H7 infection in school children in Sakai City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol. 1999;150:787–796.
- [46]. Morabito S, Tozzoli R, Oswald E, Caprioli A. A mosaic pathogenicity island made up of the locus of enterocyte effacement and a pathogenicity island of Escherichia coli O157:H7 is frequently present in attaching and effacing E. coli. Infect Immun. 2003;71:3343–3348.
- [47]. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev. 1998;11:142–201.
- [48]. Naylor SW, Low JC, Besser TE, Mahajan A, Gunn GJ, Pearce MC, McKendrick IJ, Smith DGE, Gally DL. Lymphoid follicle-dense mucosa at the terminal rectum is the principal site of colonization of enterohemorrhagic Escherichia

- coli O157:H7 in the bovine host. *Infect Immun.* 2003;71:1505–1512.
- [49]. Orndorff PE, Wang Y, Huang SH, Wass CA, Stins MF, Kim KS. The gene locus *yijP* contributes to *Escherichia coli* K1 invasion of brain microvascular endothelial cells. *Infect Immun.* 1999;67:4751–4756.
- [50]. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobayashi JM. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in *Escherichia coli* O157:H7 infections. *J Infect Dis.* 1989;160:994–998.
- [51]. Paton AW, Paton JC. Direct detection of Shiga toxinogenic *Escherichia coli* strains belonging to serogroups O111, O157, and O113 by multiplex PCR. *J Clin Microbiol.* 1999;37:3362–3365.
- [52]. Perna NT, Mayhew GF, Posfai G, Elliott S, Donnenberg MS, Kaper JB, Blattner FR. Molecular evolution of a pathogenicity island from enterohemorrhagic *Escherichia coli* O157:H7. *Infect Immun.* 1998;66:3810–3817.
- [53]. Perna NT, Plunkett G, Burland V, Mau B, Glasner JD, Rose DJ, et al. Genome sequence of enterohaemorrhagic *Escherichia coli* O157:H7. *Nature.* 2001;409:529–533.
- [54]. Peterson WL, Mackowiak PA, Barnett CC, Marling-Cason M, Haley ML. The human gastric bactericidal barrier: Mechanisms of action, relative antibacterial activity, and dietary influences. *J Infect Dis.* 1989;159:979–983.
- [55]. Putonti C, Luo Y, Katili C, Chumakov S, Fox GE, Graur D, Fofanov Y. A computational tool for the genomic identification of regions of unusual compositional properties and its utilization in the detection of horizontally transferred sequences. *Mol Biol Evol.* 2006;23:1863–1868.
- [56]. Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. Epidemiology of *Escherichia coli* O157:H7 outbreaks, United States, 1982–2002. *Emerg Infect Dis.* 2005;11:603–609.
- [57]. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, et al. Hemorrhagic colitis associated with a rare *Escherichia coli* serotype. *N Engl J Med.* 1983;308:681–685.
- [58]. Sanderson MW, Besser TE, Gay JM, Gay CC, Hancock DD. Fecal *Escherichia coli* O157:H7 shedding patterns of orally inoculated calves. *Vet Microbiol.* 1999;69:199–205.
- [59]. Saxena SK, O'Brien AD, Ackerman EJ. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28S RNA when microinjected into *Xenopus* oocytes. *J Biol Chem.* 1989;264:596–601.
- [60]. Schlech WF, III, Chase DP, Badley A. A model of food-borne *Listeria monocytogenes* infection in the Sprague–Dawley rat using gastric inoculation: Development and effect of gastric acidity on infective dose. *Int J Food Microbiol.* 1993;18:15–24.
- [61]. Schmidt H, Beutin L, Karch H. Molecular analysis of the plasmid-encoded hemolysin of *Escherichia coli* O157:H7 strain EDL 933. *Infect Immun.* 1995;63:1055–1061.
- [62]. Schmidt H, Henkel B, Karch H. A gene cluster closely related to type II secretion pathway operons of Gram-negative bacteria is located on the large plasmid of enterohemorrhagic *Escherichia coli* O157 strains. *FEMS Microbiol Lett.* 1997;148:265–272.
- [63]. Schmidt H, Karch H, Beutin L. The large-sized plasmids of enterohemorrhagic *Escherichia coli* O157 strains encode hemolysins which are presumably members of the *E. coli* alpha-hemolysin family. *FEMS Microbiol Lett.* 1994;117:189–196.
- [64]. Sheng H, Lim JY, Knecht HJ, Li J, Hovde CJ. Role of *Escherichia coli* O157:H7 virulence factors in colonization at the bovine terminal rectal mucosa. *Infect Immun.* 2006;74:4685–4693.
- [65]. Shima K, Yoshii N, Akiba M, Nishimura K, Nakazawa M, Yamasaki S. Comparison of PCR–RFLP and PFGE for determining the clonality of enterohemorrhagic *Escherichia coli* strains. *FEMS Microbiol Lett.* 2006;257:124–131.
- [66]. Stevens MP, Roe AJ, Vlisidou I, Van Diemen PM, La Ragione RM, Best A,

- Woodward MJ, Gally DL, Wallis TS. Mutation of *toxB* and a truncated version of the *efa-1* gene in *Escherichia coli* O157:H7 influences the expression and secretion of locus of enterocyte effacement-encoded proteins but not intestinal colonization in calves or sheep. *Infect Immun*. 2004;72:5402–5411.
- [67]. Tatsuno I, Horie M, Abe H, Miki T, Makino K, Shinagawa H, Taguchi H, Kamiya S, Hayashi T. *toxB* gene on pO157 of enterohemorrhagic *Escherichia coli* O157:H7 is required for full epithelial cell adherence phenotype. *Infect Immun*. 2001;69:6660–6669.
- [68]. Thompson JS, Hodge DS, Borczyk AA. Rapid biochemical test to identify verocytotoxin-positive strains of *Escherichia coli* serotype O157. *J Clin Microbiol*. 1990;28:2165–2168.
- [69]. van Diemen PM, Dziva F, Stevens MP, Wallis TS. Identification of enterohemorrhagic *Escherichia coli* O26:H-genes required for intestinal colonization in calves. *Infect Immun*. 2005;73:1735–1743.
- [70]. Varma JK, Greene KD, Reller ME, DeLong SM, Trottier J, Nowicki SF, et al. An outbreak of *Escherichia coli* O157 infection following exposure to a contaminated building. *JAMA*. 2003;290:2709–2712.
- [71]. Wells JG, Davis BR, Wachsmuth IK, Riley LW, Remis RS, Sokolow R, Morris GK. Laboratory investigation of hemorrhagic colitis outbreaks associated with a rare *Escherichia coli* serotype. *J Clin Microbiol*. 1983;18:512–520.
- [72]. Wick LM, Qi W, Lacher DW, Whittam TS. Evolution of genomic content in the stepwise emergence of *Escherichia coli* O157:H7. *J Bacteriol*. 2005;187:1783–1791.
- [73]. Willshaw GA, Smith HR, Cheasty T, Wall PG, Rowe B. Vero cytotoxin-producing *Escherichia coli* O157 outbreaks in England and Wales, 1995: Phenotypic methods and genotypic subtyping. *Emerg Infect Dis*. 1997;3:561–565.
- [74]. Yoon JW, Hovde CJ. All blood, no stool: Enterohemorrhagic *Escherichia coli* O157:H7 infection. *J Vet Sci*. 2008;9:219–231.
- [75]. Yoon JW, Lim JY, Park YH, Hovde CJ. Involvement of the *Escherichia coli* O157:H7(pO157) *ecf* operon and lipid A myristoyl transferase activity in bacterial survival in the bovine gastrointestinal tract and bacterial persistence in farm water troughs. *Infect Immun*. 2005;73:2367–2378.
- [76]. Yoon JW, Minnich SA, Ahn JS, Park YH, Paszczynski A, Hovde CJ. Thermoregulation of the *Escherichia coli* O157:H7 pO157 *ecf* operon and lipid A myristoyl transferase activity involves intrinsically curved DNA. *Mol Microbiol*. 2004;51:419–435.
- [77]. Yuk HG, Marshall DL. Adaptation of *Escherichia coli* O157:H7 to pH alters membrane lipid composition, verotoxin secretion, and resistance to simulated gastric fluid acid. *Appl Environ Microbiol*. 2004;70:3500–3505.